--- title: "Acurx Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/285988887.md" datetime: "2026-05-11T20:09:12.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285988887.md) - [en](https://longbridge.com/en/news/285988887.md) - [zh-HK](https://longbridge.com/zh-HK/news/285988887.md) --- # Acurx Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.62, missing the estimate of USD -0.59. EBIT: As of FY2026 Q1, the actual value is USD -1.751 M. Acurx Pharmaceuticals, Inc. manages its business as a single segment and has not generated any revenue since its inception, with no expectation of product sales revenue in the near future. #### Operational Metrics (Three Months Ended March 31) - **Net Loss**: The net loss for the three months ended March 31, 2026, was - $1,681,000, decreasing by -22% from - $2,149,000 in the same period of 2025. - **Operating Loss**: The operating loss was - $1,716,000 for the three months ended March 31, 2026, a -21% decrease compared to - $2,176,000 for the three months ended March 31, 2025. - **Research and Development (R&D) Expenses**: R&D expenses decreased by -43% to $341,000 for the three months ended March 31, 2026, from $599,000 in the prior year. This reduction was primarily due to a - $100,000 decrease in manufacturing-related costs and a - $200,000 decrease in consulting fees, as the previous year had higher expenses related to Phase 2b and Phase 3 preparation. - **General and Administrative (G&A) Expenses**: G&A expenses decreased by -13% to $1,375,000 for the three months ended March 31, 2026, from $1,577,000 for the same period in 2025. This was mainly attributed to a - $100,000 decrease in professional fees and a - $100,000 decrease in legal fees. - **Interest Income**: Interest income increased by 30% to $35,000 for the three months ended March 31, 2026, from $27,000 in the comparable period of 2025. #### Cash Flow (Three Months Ended March 31) - **Net Cash Used in Operating Activities**: Net cash used in operating activities was - $1,408,000 for the three months ended March 31, 2026, an improvement from - $2,051,000 for the same period in 2025. - **Net Cash Provided by Financing Activities**: Net cash provided by financing activities was $3,106,000 for the three months ended March 31, 2026, primarily from sales related to an equity line of credit purchase agreement, compared to $2,989,000 from Registered Direct Offerings in 2025. - **Net Increase in Cash**: The company experienced a net increase in cash of $1,698,000 for the three months ended March 31, 2026, up from $938,000 in the prior year period. - **Cash Balance**: As of March 31, 2026, the cash balance was $9,254,813, compared to $4,643,887 as of March 31, 2025. #### Liquidity and Capital Resources As of March 31, 2026, Acurx Pharmaceuticals, Inc. reported cumulative losses of approximately - $77.0 million and working capital of $7.0 million, including approximately $9.3 million in cash. Management believes existing capital resources are insufficient for the next 12 months, raising substantial doubt about its ability to continue as a going concern, and plans to seek additional equity financing and grant funding. #### Strategic Outlook and Recent Developments Acurx Pharmaceuticals, Inc. is expanding its ibezapolstat program into recurrent _C. difficile_ infection (rCDI) with an open-label pilot trial for up to 20 patients, expected to begin enrollment in the fourth quarter of 2026. Data from this study will inform the design of a planned active-controlled Phase 3 registration trial in rCDI, aiming for FDA approval under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD). In April 2026, the company completed a registered direct offering and concurrent private placement, raising approximately $2.5 million in gross proceeds. Additionally, through May 11, 2026, the company sold an additional 67,484 shares of common stock for approximately $0.2 million under an equity line of credit purchase agreement, bringing cumulative gross proceeds to approximately $7.3 million. ### Related Stocks - [ACXP.US](https://longbridge.com/en/quote/ACXP.US.md) ## Related News & Research - [PowerFleet Q4 2026 Earnings Preview](https://longbridge.com/en/news/289616465.md) - [Gamehaus Holdings Inc. Announces Unaudited Financial Results for the Third Quarter of Fiscal 2026 Ended March 31, 2026 | GMHS Stock News](https://longbridge.com/en/news/289035965.md) - [Soybean Analysis: 2026 Market Volatility and Trend](https://longbridge.com/en/news/289444628.md) - [ABB Ltd: ABB share buybacks - June 4, 2026 – June 10, 2026](https://longbridge.com/en/news/289436946.md) - [3 High-Yield (7%+) Bond ETFs for Income-Seeking Investors to Buy in 2026](https://longbridge.com/en/news/289655624.md)